Description
EIDD-2801 (Molnupiravir) is an orally bioavailable broad spectrum antiviral compound that is effective against SARS-CoV2 infection.
EIDD-2801
Product ID E325125
Cas No. 2349386-89-4, 2492423-29-5
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 2349386-89-4, 2492423-29-5 |
|---|---|
| Purity | ≥98% |
| Formula | C13H19N3O7 |
| Formula Wt. | 329.3 |
| Chemical Name | N-Hydroxy-5'-O-isobutyryl-3,4-dihydrocytidine |
| IUPAC Name | [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate |
| Synonym | Molnupiravir; EIDD 2801; EIDD2801; MK-4482; β-D-N4-Hydroxycytidine-5′-isopropyl ester |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Sheahan TP, Sims AC, Zhou S. et al An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. scitranslmed.abb5883. Epub 2020 Apr 6. PMID: 32253226 PMCID: PMC7164393 DOI: 10.1126/scitranslmed.abb5883
Fischer W, Eron JJ, Holman W. et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. MedRxiv. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639. Preprint. PMID: 34159342
Abdelnabi R, Foo CS, De Jonghe S. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. J Infect Disactions. 2021 Sep 1;224(5):749-753. doi: 10.1093/infdis/jiab361. PMID: 34244768 PMCID: PMC8408768 DOI: 10.1093/infdis/jiab361
Kabinger F, Stiller C, Schmitzova J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature Structural & Molecular Biology. 2021 Sep;28(9):740-746. PMID: 34381216.
Gordon CJ, Tchesnokov EP, Schinazi RF, et al. Molnupiravir promotes SARV-CoV-2 mutagenesis via the RNA template. J Biological Chem. 2021 Jul;297(1):100770. PMID: 33989635.